Journal of Reports in Pharmaceutical Sciences
A Study on the DNA Cleavage, Morphological Changes and Cytotoxicity Activities of the Two Synthetic COX-2 Inhibitors
Abstract
Celecoxib, a specific cyclooxygenase-2 (COX-2) inhibitor, has been proven to possess antitumor activity in a variety of cancer cells. However, the antitumor activity of two synthesized COX-2 inhibitor derivatives (A and B) on human myeloid leukemia (K562) and breast adenocarcinoma (MCF-7) cancer cells has not been well established. The present study is aimed to investigate the morphological changes of cells treated with compounds A and B as well as DNA cleavage activity of these compounds. The DNA cleavage experiments were performed by agarose gel electrophoresis. Plasmid pTZ57 DNA was treated with the compounds A and B at various concentrations. Then, bands visualized by UV light and photographed to determine the extent of cleavage of the supercoiled (SC) to Nicked (NC) DNA. Furthermore, the apoptotic activities of the two compounds were assessed using cells treated with DAPI staining method. The results obtained from DNA cleavage assay demonstrated that with the increasing concentration of compound A, SC DNA is gradually converted to NC DNA. Cells were also exposed to various concentrations (0.1-100 μM) of each compound for 24 h. Two compounds demonstrated the cytotoxic effects on MCF-7 and K562 cell lines in a concentration-dependent manner with the IC50 values ranging from 6.5 to 22.23 μM. Treatment of the cells with compounds A and B significantly cause morphological changes after 16 h. Collectively, our data indicate that compounds A and B as two COX-2 inhibitor derivatives may present promising chemotherapeutic activities, possibly targeting DNA and inducing cell death in the selected cancer cell line which needs further research.
Copyright
© 2013, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
Cytotoxicity of Selected Novel Chalcone Derivatives on Human Breast, Lung and Hepatic Carcinoma Cell Lines
Nakhjavani M, Zarghi A, H. Shirazi F. Cytotoxicity of Selected Novel Chalcone Derivatives on Human Breast, Lung and Hepatic Carcinoma Cell Lines. Iran J Pharm Res. 2014;13(3):e125496. doi: https://doi.org/10.22037/ijpr.2014.1548
Necrotic Effect versus Apoptotic Nature of Camptothecin in Human Cervical Cancer Cells
Zare-Mirakabadi A, Sarzaeem A, Moradhaseli S, Sayad A, Negahdary M. Necrotic Effect versus Apoptotic Nature of Camptothecin in Human Cervical Cancer Cells. Int J Cancer Manag. 2012;5(3):e80810. doi:
A New Survey about Dual-Acting PARP/COX-2 Inhibitors as Cancer Chemopreventive Agents
Ismail Mahboubi Rabbani M, Aliabadi A, Bayat L, Jafari M, Bagheri AH, et al. A New Survey about Dual-Acting PARP/COX-2 Inhibitors as Cancer Chemopreventive Agents. Iran J Pharm Res. 2026;25(1):e169140. doi: https://doi.org/10.5812/ijpr-169140
Design, Synthesis and Cytotoxicity Evaluation of New 2-Aryl-5, 6-Dihydropyrrolo[2, 1-a]Isoquinoline Derivatives as Topoisomerase Inhibitors
Kakhki S, Shahosseini S, Zarghi A. Design, Synthesis and Cytotoxicity Evaluation of New 2-Aryl-5, 6-Dihydropyrrolo[2, 1-a]Isoquinoline Derivatives as Topoisomerase Inhibitors. Iran J Pharm Res. 2014;13(Suppl):e125435. doi: https://doi.org/10.22037/ijpr.2014.1460
Synthesis and Cytotoxicity Study of New Cyclopenta [b] quinoline-1,8-dione Derivatives
Miri R, Firuzi O, Peymani P, Nazarian Z, Shafiee A. Synthesis and Cytotoxicity Study of New Cyclopenta [b] quinoline-1,8-dione Derivatives. Iran J Pharm Res. 2011;10(3):e125954. doi: https://doi.org/10.22037/ijpr.2011.1005
- Scopus by DOI: 0
Last Update: 2 weeks ago
- Scopus by Title: 1
Last Update: 2 weeks ago
- Scopus by Title (Ref): 1
Last Update: 2 weeks ago
- CrossRef: 0
Last Update: 6 days ago
Ordering Reprints
Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC
Author(s):